Literature DB >> 27783227

The simulation of UV spectroscopy and electronic analysis of temozolomide and dacarbazine chemical decomposition to their metabolites.

M Hossein Khalilian1, Saber Mirzaei1, Avat Arman Taherpour2,3.   

Abstract

The electronic features of anti-tumor agent, temozolomide, and its degradation products (MTIC and metabolite AIC) have been traced by means of UV absorption spectroscopy in vacuo and aqueous media. For comparison, electronic spectra of related structures and drugs (e.g., dacarbazine) were also investigated. These investigations were carried out using time-dependent density functional theory (TD-DFT) method while the conductor like screening model (COSMO) were applied for the inclusion of solvent effects in electronic spectra. From functional benchmarking, two methods; B3LYP and O3LYP were selected among several other methods with 6-311+G(2d,p) basis set aiming to get the best results in accord with the experimental values. An assessment of the obtained spectra has shown that O3LYP functional gives a mean absolute error (MAE) from experimental absorption peaks of 4.3 nm compared to the 7.2 nm MAE value at B3LYP level in aqueous media. Furthermore, since the structural and tautomeric conformers affect the electronic spectra, conformational preferences have been analyzed in temozolomide, dacarbazine, and their related structures. Temozolomide structure possesses two rotamers that differ in the orientation of carboxamide moiety with a small energy difference (energy difference of 1.39 kcal mol-1 in vacuo and 0.35 kcal mol-1 in aqueous media at B3LYP/6-311++G(2df,3pd). The more stable and meta-stable TMZ rotamer have shown their absorption maxima at 329-334 nm, respectively, at O3LYP level in aqueous media. Applying statistical calculation according to Boltzmann population formula at 25 °C and computed weighed mean estimates the λmax of temozolomide at 331 nm, which is in notable agreement with the experimental value (330 nm). Moreover, molecular orbital composition analysis has been conducted in order to interpret these findings. Graphical Abstract Temozolomide and dacarbazine.

Entities:  

Keywords:  Conformational analysis; Dacarbazine; O3LYP; TD-DFT; Temozolomide; UV Spectroscopy

Mesh:

Substances:

Year:  2016        PMID: 27783227     DOI: 10.1007/s00894-016-3133-7

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  25 in total

1.  Generalized Gradient Approximation Made Simple.

Authors: 
Journal:  Phys Rev Lett       Date:  1996-10-28       Impact factor: 9.161

2.  Degradation of dacarbazine in aqueous solution.

Authors:  B V Shetty; R L Schowen; M Slavik; C M Riley
Journal:  J Pharm Biomed Anal       Date:  1992-09       Impact factor: 3.935

3.  Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density.

Authors: 
Journal:  Phys Rev B Condens Matter       Date:  1988-01-15

4.  Determination of temozolomide in serum and brain tumor with micellar electrokinetic capillary chromatography.

Authors:  Melinda Andrási; Brigitta Törzsök; Álmos Klekner; Attila Gáspár
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-06-13       Impact factor: 3.205

Review 5.  New approaches in the treatment of metastatic melanoma: thalidomide and temozolomide.

Authors:  W J Hwu
Journal:  Oncology (Williston Park)       Date:  2000-12       Impact factor: 2.990

6.  Crystal engineering of stable temozolomide cocrystals.

Authors:  N Jagadeesh Babu; Palash Sanphui; Ashwini Nangia
Journal:  Chem Asian J       Date:  2012-05-21

Review 7.  Temozolomide and treatment of malignant glioma.

Authors:  H S Friedman; T Kerby; H Calvert
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

8.  Phase I clinical trial of mitozolomide.

Authors:  E S Newlands; G Blackledge; J A Slack; C Goddard; C J Brindley; L Holden; M F Stevens
Journal:  Cancer Treat Rep       Date:  1985 Jul-Aug

Review 9.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.

Authors:  P Vaupel; F Kallinowski; P Okunieff
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

10.  Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamide.

Authors:  L L Tsang; C P Quarterman; A Gescher; J A Slack
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

View more
  4 in total

1.  Triple conjugated carbon dots as a nano-drug delivery model for glioblastoma brain tumors.

Authors:  Sajini D Hettiarachchi; Regina M Graham; Keenan J Mintz; Yiqun Zhou; Steven Vanni; Zhilli Peng; Roger M Leblanc
Journal:  Nanoscale       Date:  2019-03-28       Impact factor: 7.790

2.  Development and Full Validation of a Stability-indicating HPLC Method for the Determination of the Anticancer Drug Temozolomide in Pharmaceutical Form.

Authors:  Evin Kapçak; Eda Hayriye Şatana-Kara
Journal:  Turk J Pharm Sci       Date:  2018-11-20

3.  Comprehensive study on the degradation of ochratoxin A in water by spectroscopic techniques and DFT calculations.

Authors:  Iris Cagnasso; Glauco Tonachini; Silvia Berto; Agnese Giacomino; Luisa Mandrile; Andrea Maranzana; Francesca Durbiano
Journal:  RSC Adv       Date:  2019-06-27       Impact factor: 4.036

4.  The Interaction of Temozolomide with Blood Components Suggests the Potential Use of Human Serum Albumin as a Biomimetic Carrier for the Drug.

Authors:  Marta Rubio-Camacho; José A Encinar; María José Martínez-Tomé; Rocío Esquembre; C Reyes Mateo
Journal:  Biomolecules       Date:  2020-07-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.